MedPath

Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens

Not Applicable
Completed
Conditions
Refractive Ametropia
Interventions
Device: etafilcon A control lens (1DM)
Device: etafilcon A with print and PVP for light eyes (EALE)
Device: etafilcon A with print and PVP for dark eyes (EADE)
Registration Number
NCT01484028
Lead Sponsor
Johnson & Johnson Vision Care, Inc.
Brief Summary

This study will serve to evaluate and compare the performance of two new lenses to a marketed lens.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
275
Inclusion Criteria
  • Healthy, female adult, at least 18 years of age, and no more than 34 years of age
  • The subjects must be female, light eye Caucasian, Non-Hispanic, habitual soft contact lens wearer (both eyes) with light or dark eyes
  • Must have rated the Concept Statement positively (i.e., a rating of 4 or 5).
  • Optimal vertexed spherical equivalent distance correction must be between -1.00 and -4.00 diopters (D)
  • Any cylinder power must be: <=0.75D
  • Visual acuity must be best correctable to 20/25 or better for each eye
  • Must have normal eyes (no ocular medications or ocular infection of any type)
  • Must read and sign the Statement of Informed Consent
  • Must appear able and willing to adhere to the instructions set forth in this clinical protocol.
Exclusion Criteria
  • Ocular or systemic allergies or disease which might interfere with contact lens wear
  • Systemic disease, autoimmune disease, or use of medication which might interfere with contact lens wear
  • Clinically significant (grade 3 or worse) corneal edema, corneal neovascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear
  • Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear
  • Any ocular infection
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear
  • Any color deficiencies (colorblindness) - to the best of the subject's knowledge
  • Pregnancy or lactation
  • Diabetes
  • Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease (e.g. HIV)
  • Habitual contact lens type is toric, multifocal, or is worn as extended wear.
  • Subject presents with one dark iris color and one light iris color.
  • Subject has heterochromia iridis (a difference in color between parts of one iris).
  • The subject must not be an employee or family member of the clinical study site.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
1DM/EADEetafilcon A control lens (1DM)etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for dark eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
EALE/1DMetafilcon A control lens (1DM)etafilcon A with PVP for light eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
EADE/1DMetafilcon A control lens (1DM)etafilcon A with PVP for dark eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
EALE/1DMetafilcon A with print and PVP for light eyes (EALE)etafilcon A with PVP for light eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
EADE/1DMetafilcon A with print and PVP for dark eyes (EADE)etafilcon A with PVP for dark eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
1DM/EADEetafilcon A with print and PVP for dark eyes (EADE)etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for dark eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
1DM/EALEetafilcon A control lens (1DM)etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for light eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
1DM/EALEetafilcon A with print and PVP for light eyes (EALE)etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for light eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
Primary Outcome Measures
NameTimeMethod
Lens Fit AcceptanceDispensing

The overall lens fit was evaluated by the Investigators for each eye whether it was acceptable (yes/no).

Monocular Visual AcuityDispensing

Monocular distance Snellen visual acuity (VA) scores were coverted to the algorithm of the minimal angle of resolution (LogMAR) scale based on the following formula: LogMAR = Log10 (VA/20) - a\*VAR, where Log10 = base 10 logarithm, VA = the Snellen denominator score, a = LogMAR stepsize coefficient and VAR = letter gained or missing in addition to the Snellen denominator score.

Corneal Staining of Grade 3 or 4After 7-9 days of lens wear

Corneal staining was graded using a 5-point scale; 0=None(no staining), 1=Trace, 2=Mild, 3=Moderate, and 4=Severe. Only those eyes with corneal staining grade \>= 3 were reported.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (15)

Kannarr Eye Care

🇺🇸

Pittsburg, Kansas, United States

Snowy Range Cision Center

🇺🇸

Laramie, Wyoming, United States

Isthmus Eye Care

🇺🇸

Middleton, Wisconsin, United States

The Eye Care Group

🇺🇸

Grants Pass, Oregon, United States

Eye Associates of Winter Park

🇺🇸

Winter Park, Florida, United States

Advance Eye Care

🇺🇸

Pismo Beach, California, United States

James R Dugue, Optometrist

🇺🇸

Mission Viejo, California, United States

Advanced Optometry

🇺🇸

Mission Viejo, California, United States

Golden Vision

🇺🇸

Sarasota, Florida, United States

Eye Care Associates

🇺🇸

Bloomington, Illinois, United States

Sacco Eye Group

🇺🇸

Vestal, New York, United States

Spectrum Eye Care

🇺🇸

Jamestown, New York, United States

Dr. David W Ferris and Associates

🇺🇸

Warwick, Rhode Island, United States

Wishnow Sugar Group

🇺🇸

Katy, Texas, United States

Vision Care

🇺🇸

East Lansing, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath